Mind Medicine (MindMed) Inc.

NasdaqGS MNMD

Mind Medicine (MindMed) Inc. Total Assets for the year ending December 31, 2023

Mind Medicine (MindMed) Inc. Total Assets is NA for the year ending December 31, 2023. Total assets are the total value of all assets owned by a company, representing its resources.
Key data
Date Total Assets Current Liabilities Total Non-Current Liabilities Shareholders' Equity
Market news
Loading...
NasdaqGS: MNMD

Mind Medicine (MindMed) Inc.

CEO Mr. Robert Barrow
IPO Date Nov. 15, 2016
Location Canada
Headquarters 1055 West Hastings Street
Employees 57
Sector Health Care
Industries
Description

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

Similar companies

OPT

Opthea Limited

USD 3.82

6.70%

ATAI

Atai Life Sciences N.V.

USD 1.33

-6.34%

ITOS

iTeos Therapeutics, Inc.

USD 7.66

-1.80%

CKPT

Checkpoint Therapeutics, Inc.

USD 3.17

-0.94%

EWTX

Edgewise Therapeutics, Inc.

USD 27.52

8.65%

BPTH

Bio-Path Holdings, Inc.

USD 0.84

-10.07%

VCNX

Vaccinex, Inc.

USD 1.05

0.00%

CYBN

Cybin Inc.

USD 8.83

-0.79%

GHRS

GH Research PLC

USD 8.19

-1.92%

KOD

Kodiak Sciences Inc.

USD 7.60

-2.69%

RVPH

Reviva Pharmaceuticals Holdings, Inc.

USD 1.58

-17.28%

StockViz Staff

January 15, 2025

Any question? Send us an email